1.1100
29-11月-24 13:45:00
15 分の遅延
株式
+0.0600
+5.71%
本日の幅
1.0500 - 1.1100
ISIN
N/A
ソース
NASDAQ
Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021
11 2 2021 09:12:54 提供 Nasdaq GlobeNewswire
Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase
20 1 2021 07:00:00 提供 Nasdaq GlobeNewswire
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
06 1 2021 07:00:01 提供 Nasdaq GlobeNewswire